Plasma p‐tau217 detects Alzheimer’s disease co‐pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort

by Clinical Neuropsychologist Online | Wednesday, August 5, 2026 | Dementia

Abstract INTRODUCTION Cerebral amyloid angiopathy (CAA) frequently co-occurs with Alzheimer’s disease (AD), generating mixed vascular–neurodegenerative phenotypes. Plasma phosphorylated tau (p-tau)217 is a robust biomarker of AD, but its performance in CAA...

Further data to address the Alzheimer’s coverage with evidence development questions

by Clinical Neuropsychologist Online | Wednesday, August 5, 2026 | Dementia

Abstract INTRODUCTION Medicare patients currently access amyloid-targeting therapies for Alzheimer’s disease through the class-based National Coverage Determination (NCD) with coverage with evidence development (CED) established in 2022. Evidence addressing the...

The role of polygenic risk in Alzheimer’s disease prediction for African Americans

by Clinical Neuropsychologist Online | Wednesday, August 5, 2026 | Dementia

Abstract INTRODUCTION African Americans (AAs) face a higher risk of Alzheimer’s disease and related dementias (ADRD) than European Americans (EUs), yet the utility of polygenic risk scores (PRS) in AAs remains underexplored. METHODS A standardized dementia PRS...

Lower cardiac output is a risk factor for faster cerebral atrophy over a 11‐year follow‐up period in APOE‐ε4 carriers

by Clinical Neuropsychologist Online | Tuesday, August 4, 2026 | Dementia

Abstract INTRODUCTION Subclinical lower cardiac output (volume of blood pumped per minute) cross-sectionally relates to smaller cerebral gray matter volumes in older adults. This study relates cardiac output to longitudinal gray matter volumes among middle-aged and...

Visit‐to‐visit systolic blood pressure variability, blood pressure treatment intensity, and cognitive decline

by Clinical Neuropsychologist Online | Friday, July 31, 2026 | Dementia

Abstract INTRODUCTION Visit-to-visit blood pressure variability (BPV) may be associated with cognitive decline beyond mean blood pressure (BP), but its relevance across treatment contexts remains uncertain. METHODS We pooled individual-participant data from Action to...

From mapping evidence to engaging voices: Paving the way for research on the social determinants of dementia

by Clinical Neuropsychologist Online | Friday, July 31, 2026 | Dementia

Alzheimer’s &Dementia, Volume 22, Issue 8, August 2026. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | July 31, 2026 Neuro-Dementia Previous...